WBA lowered its fiscal 2024 adjusted EPS guidance to $2.80 to $2.95 reflecting challenging pharmacy industry trends and a worse-than-expected U.S. consumer environment.
The portfolio to be acquired consists of global NRT brand Nicotinell and local brands Nicabate, Habitrol and Thrive in markets outside of the United States.